{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-topical-skin-nose-eyes/management/eye-treatment/","result":{"pageContext":{"chapter":{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment","depth":2,"htmlHeader":"<!-- begin field 822477fe-d0b5-4917-80a0-4f3637f00f30 --><h2>Scenario: Eye treatment</h2><!-- end field 822477fe-d0b5-4917-80a0-4f3637f00f30 -->","summary":"Covers the management of people receiving corticosteroid eye preparations. Although corticosteroid eye preparations are initiated in secondary care, treatment may be continued and monitored in primary care following specialist agreement.","htmlStringContent":"<!-- begin item 21297169-371e-476c-b2f0-c2c8986e8316 --><!-- begin field 638f943c-307a-4e9a-a41f-acd900ab0ce7 --><p>From birth onwards.</p><!-- end field 638f943c-307a-4e9a-a41f-acd900ab0ce7 --><!-- end item 21297169-371e-476c-b2f0-c2c8986e8316 -->","topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","lastRevised":"Last revised in September 2020","chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"1445c8e0-f325-5388-8b1b-c2444a7b8e65","slug":"initiation","fullItemName":"Initiation","depth":3,"htmlHeader":"<!-- begin field fa7ae88a-e923-41c3-9de4-0f7970b3dbed --><h3>What should I know about the initiation of corticosteroid eye preparations?</h3><!-- end field fa7ae88a-e923-41c3-9de4-0f7970b3dbed -->","summary":null,"htmlStringContent":"<!-- begin item 5f40e8e8-91b4-4afc-a414-c03311a5f6b6 --><!-- begin field 25747156-a2c4-4129-bd07-17edb4458f0a --><ul><li><strong>Treatment with corticosteroid eye preparations should always be initiated in secondary care by a specialist. </strong>However, treatment may be continued and monitored in primary care following a specialist management plan.</li></ul><!-- end field 25747156-a2c4-4129-bd07-17edb4458f0a --><!-- end item 5f40e8e8-91b4-4afc-a414-c03311a5f6b6 -->","subChapters":[{"id":"332b3886-e229-5959-a408-f93a2e3ba129","slug":"basis-for-recommendation-24a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 595b3171-ef30-4857-909f-3a4f83f8785b --><h4>Basis for recommendation</h4><!-- end field 595b3171-ef30-4857-909f-3a4f83f8785b -->","summary":null,"htmlStringContent":"<!-- begin item 24ab1b4a-417c-46f0-90c0-ca612c957fe0 --><!-- begin field cc0ab402-ea25-45e0-a5b8-feccc9eda737 --><p>This recommendation is based on information in the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</p><ul><li>Corticosteroid eye preparations should be used only under specialist supervision, as there are potential complications associated with their use:<ul><li>An undiagnosed red eye may be due to herpes simplex virus, and the use of corticosteroid eye preparations may worsen the condition, leading to corneal ulceration and possible loss of vision. The same risks may be seen with bacterial, fungal, and amoebic infections.</li><li>Susceptible people may develop corticosteroid-induced glaucoma and/or cataract following the use of corticosteroid eye preparations.</li></ul></li></ul><!-- end field cc0ab402-ea25-45e0-a5b8-feccc9eda737 --><!-- end item 24ab1b4a-417c-46f0-90c0-ca612c957fe0 -->","subChapters":[]}]},{"id":"e2191a95-50f1-5da3-b75d-1cf742bb0c49","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 80743694-80ea-4c10-8b4b-eaec6d511c89 --><h3>What contraindications and cautions are associated with corticosteroid eye preparations?</h3><!-- end field 80743694-80ea-4c10-8b4b-eaec6d511c89 -->","summary":null,"htmlStringContent":"<!-- begin item bb64f73b-c59f-4ba1-a963-5ecbd4b7e3d9 --><!-- begin field 21224724-7ece-4ab3-867a-63a75c1c9ad7 --><p><strong>Treatment with corticosteroid eye preparations should always be initiated in secondary care by a specialist. </strong>However, treatment may be continued and monitored in primary care following a specialist management plan.</p><ul><li>Corticosteroid eye preparations should be avoided in people with:<ul><li>Bacterial, viral, fungal tuberculous, or purulent eye conditions.</li><li>Herpetic keratitis. </li><li>Glaucoma. </li><li>Perforation, ulceration, or injury. </li><li>Soft contact lenses — lenses should be removed before instillation of drops, and not worn during the period of treatment. </li></ul></li><li>Prescribe corticosteroid eye preparations with caution to people with:<ul><li>A personal or family history of diabetes.</li></ul></li></ul><!-- end field 21224724-7ece-4ab3-867a-63a75c1c9ad7 --><!-- end item bb64f73b-c59f-4ba1-a963-5ecbd4b7e3d9 -->","subChapters":[{"id":"25e5a777-9ce8-59c5-a435-4d03f64581be","slug":"basis-for-recommendation-e3c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c96bbe5d-3786-4eaf-851f-8bde6bd3a310 --><h4>Basis for recommendation</h4><!-- end field c96bbe5d-3786-4eaf-851f-8bde6bd3a310 -->","summary":null,"htmlStringContent":"<!-- begin item e3c4315f-f239-4a32-9864-e45d149363cc --><!-- begin field 6846d05f-fa07-4d71-8e5f-9875fecb6d68 --><p>These recommendations are based on the manufacturers' summaries of product characteristics for Dexafree unit dose drops [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2018a</a>] and prednisolone eye drops [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019e</a>], and the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 6846d05f-fa07-4d71-8e5f-9875fecb6d68 --><!-- end item e3c4315f-f239-4a32-9864-e45d149363cc -->","subChapters":[]}]},{"id":"58286f90-3c31-55b1-aea6-4cd44d02acb3","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 96300511-bedb-43ee-8cef-abd800dc7fe2 --><h3>Can I prescribe corticosteroid eye treatments to a woman who is pregnant or breastfeeding?</h3><!-- end field 96300511-bedb-43ee-8cef-abd800dc7fe2 -->","summary":null,"htmlStringContent":"<!-- begin item 3aaa70ea-2178-4493-bebc-abd800dc7f69 --><!-- begin field 949bbeb2-7695-4149-b459-abd800dc7fe2 --><ul><li><strong>Pregnancy</strong><ul><li>Corticosteroid eye preparations can be used in pregnancy. </li></ul></li><li><strong>Breastfeeding</strong><ul><li>​​​​​​​Corticosteroid eye preparations can be used in women who are breastfeeding.</li></ul></li></ul><!-- end field 949bbeb2-7695-4149-b459-abd800dc7fe2 --><!-- end item 3aaa70ea-2178-4493-bebc-abd800dc7f69 -->","subChapters":[{"id":"f6670196-fb59-5906-b7bc-407c48b9288b","slug":"basis-for-recommendation-204","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1a8028ec-ef57-4014-8026-abd800dc7feb --><h4>Basis for recommendation</h4><!-- end field 1a8028ec-ef57-4014-8026-abd800dc7feb -->","summary":null,"htmlStringContent":"<!-- begin item 20495c19-f3b2-42e5-af1d-abd800dc7feb --><!-- begin field bf3b965a-fefd-4024-9d92-abd800dc7feb --><ul><li><strong>Pregnancy</strong><ul><li>While data on systemic absorption of individual eye preparations are lacking, it is unlikely that ocular administration will be associated with an increased risk of fetal toxicity if the dose does not exceed that of systemic regimes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">UKTIS, 2016c</a>]. <ul><li>Systemic corticosteroids use in pregnancy has been associated with an increased risk of cleft palate and impaired fetal growth in animal models, but these outcomes have not been conclusively associated with human use. Maternal use of ocular preparations is not expected to be associated with these risks. </li></ul></li><li>The manufacturers' summaries of product characteristics state that there is inadequate data to determine the safety of corticosteroid eye preparations in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019e</a>]. <ul><li>With systemic use of corticosteroids at higher doses, intrauterine growth inhibition and inhibition of the function of the adrenal cortex have been reported, but these effects have not been reported for ocular use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2018a</a>].</li><li>Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intrauterine growth retardation, and there may be a very small risk of such effects in the human fetus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019e</a>].</li></ul></li><li>The UKTIS monograph on oral corticosteroids states that currently available data do not suggest that first trimester exposure to systemic corticosteroids in pregnancy increases the overall risk of congenital abnormalities, such as cleft lip/palate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">UKTIS, 2016b</a>]. <br><br></li></ul></li><li><strong>Breastfeeding</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SPS, 2016c</a>]<ul><li>Corticosteroid preparations for ophthalmic use have limited systemic absorption in the mother, and pose negligible risk to a breastfed infant. Systemic absorption from eye drops can be minimized by restricting passage into tear ducts immediately after administration.</li><li>There is no published evidence of safety or milk levels for any of the listed ophthalmic corticosteroids.</li></ul></li></ul><!-- end field bf3b965a-fefd-4024-9d92-abd800dc7feb --><!-- end item 20495c19-f3b2-42e5-af1d-abd800dc7feb -->","subChapters":[]}]},{"id":"edf69649-10fb-5cd8-8973-10f9593d49ef","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1a5118e3-d8d6-4452-bb34-6241fda9fbd5 --><h3>What are the adverse effects of corticosteroid eye preparations?</h3><!-- end field 1a5118e3-d8d6-4452-bb34-6241fda9fbd5 -->","summary":null,"htmlStringContent":"<!-- begin item 3e6514b0-97f9-4e02-8991-3f5f10581e43 --><!-- begin field 31155b53-4b66-4793-8efd-f98a6593ce05 --><ul><li><strong>Local adverse effects</strong><ul><li><strong>Corneal ulceration </strong>— can occur in people with ocular herpes simplex, so corticosteroid eye preparations should be avoided in such cases.</li><li><strong>Increased intraocular pressure </strong>—​​​​​​​ this may lead to optic nerve damage. Ensure the person is screened regularly for ocular hypertension and glaucoma.</li><li><strong>Cataract formation and thinning of the cornea and sclera </strong>—​​​​​​​ if the person is receiving long term corticosteroid eye preparations, refer them to the community optometrist to screen for cataract formation.</li><li><strong>Blurring of vision  </strong>—​​​​​​​ this is transient and clears within minutes.<ul><li>If blurring persists or there are other visual disturbances, consider for referral to an ophthalmologist for evaluation of possible causes that may include cataract, glaucoma, or rare diseases such as central serous chorioretinopathy. </li></ul></li><li><strong>Increased susceptibility to bacterial, viral, and fungal eye infections.</strong></li><li>Other adverse effects include chorioretinopathy, mydriasis, ptosis, epithelial punctate keratitis, corneal or scleral malaria, and corticosteroid-induced uveitis (on cessation of treatment). </li></ul></li><li><strong>Systemic adverse effects </strong>— these occur rarely, are much less likely to occur than with oral corticosteroids, and are associated with high doses prescribed for prolonged periods. </li><li><strong>Systemic adverse effects include:  </strong><ul><li>Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">Adrenal insufficiency</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li><li>Cushing's syndrome.</li><li>Visual disturbance, central serous chorioretinopathy, cataract, glaucoma.<ul><li>If a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation. </li></ul></li></ul></li><li>For more information on the systematic adverse effects of corticosteroids, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adverse-effects\">Adverse effects</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul><!-- end field 31155b53-4b66-4793-8efd-f98a6593ce05 --><!-- end item 3e6514b0-97f9-4e02-8991-3f5f10581e43 -->","subChapters":[{"id":"41c6847c-4b54-5114-a562-611f42553565","slug":"basis-for-recommendation-67f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 254505bc-14a8-4c8e-a02b-7d8989e26acb --><h4>Basis for recommendation</h4><!-- end field 254505bc-14a8-4c8e-a02b-7d8989e26acb -->","summary":null,"htmlStringContent":"<!-- begin item 67f58330-4ce9-4c37-b743-4265dc288edc --><!-- begin field 79a4db97-fa77-4a52-8fe4-176b0512bff4 --><p>These recommendations are based on the manufacturers' summaries of product characteristics for Dexafree unit dose drops [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2018a</a>], prednisolone eye drops [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019e</a>], and betamethasone eye ointment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2018b</a>]; the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>]; and the drug reference compendium <em>Martindale: the complete drug reference</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Brayfield, 2020</a>].</p><ul><li>During ophthalmic use of corticosteroids about one-third of people will develop raised intraocular pressure, usually within a few weeks of treatment with potent corticosteroids, or within months with weaker ones [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Brayfield, 2020</a>].</li><li>A Medicines and Healthcare products Regulatory Agency (MHRA) Drug Saftey update advises that there is a rare risk of central serous chorioretinopathy with local as well as systemic administration of corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MHRA, 2017</a>]. <ul><li>People should be advised to report any blurred vision or other visual disturbances during corticosteroid treatment.</li></ul></li></ul><!-- end field 79a4db97-fa77-4a52-8fe4-176b0512bff4 --><!-- end item 67f58330-4ce9-4c37-b743-4265dc288edc -->","subChapters":[]}]},{"id":"07615006-41ce-56b0-8661-2769daef5168","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 13dd59eb-2ea1-49b4-b8ba-3b812355d9ca --><h3>What information and advice should I give to a person receiving corticosteroid eye preparations?</h3><!-- end field 13dd59eb-2ea1-49b4-b8ba-3b812355d9ca -->","summary":null,"htmlStringContent":"<!-- begin item bab6298d-0e87-42bd-abfd-93d05ef7719b --><!-- begin field 41803d3d-7e88-43bf-9348-3e176c7e21ef --><ul><li>Advise the person that:<ul><li>They may experience transient blurred vision after instillation of the eye drops. They should not drive or operate heavy machinery until their vision is clear.</li><li>Corticosteroid eye preparations should not be used while wearing soft contact lenses.</li></ul></li><li>Advise the person on the correct technique to apply the drops:<ul><li>Wash and dry hands.</li><li>Do not breathe on or touch the dropper nozzle.</li><li>Tilt the head back.</li><li>Gently pull lower eyelid downwards and outwards.</li><li>Place drops in the gap between the lid and eye (squeeze bottle very gently if necessary).</li><li>Blink a few times to spread out the drops.</li><li>Repeat for the other eye if needed.</li></ul></li><li>Advise the person on the best technique to apply ointment: <ul><li>Wash and dry hands.</li><li>Tilt the head backwards.</li><li>Pull down the lower lid.</li><li>Look up and squeeze approximately 0.5 cm of ointment below the lower lid. </li><li>Take care not to touch the eye with the end of the tube. </li><li>Close the eyes.</li></ul></li></ul><!-- end field 41803d3d-7e88-43bf-9348-3e176c7e21ef --><!-- end item bab6298d-0e87-42bd-abfd-93d05ef7719b -->","subChapters":[{"id":"a21c5415-74e7-5915-bd03-a54cf06b121e","slug":"basis-for-recommendation-047","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d2e43f85-344f-4d7a-a6b1-e6fe142d96ef --><h4>Basis for recommendation</h4><!-- end field d2e43f85-344f-4d7a-a6b1-e6fe142d96ef -->","summary":null,"htmlStringContent":"<!-- begin item 0472daf8-94c1-4420-a7da-1b1ea27a6555 --><!-- begin field a1122c7d-d0b1-4677-96d2-92af47bf7fb1 --><p>These recommendations are based on the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>], the Moorfields Eye Hospital patient information leaflet <em>Corticosteroid eye drops/ointments (steroids)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Moorfields, 2017</a>], and the manufacturers' patient information leaflets for Betnesol drops [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2018c</a>] and betamethasone eye ointment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2018d</a>].</p><!-- end field a1122c7d-d0b1-4677-96d2-92af47bf7fb1 --><!-- end item 0472daf8-94c1-4420-a7da-1b1ea27a6555 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}